Enbrel and Deafness neurosensory - a phase IV clinical study of FDA data
Deafness neurosensory is found among people who take Enbrel, especially for people who are female, 60+ old, have been taking the drug for 5 - 10 years.
The phase IV clinical study analyzes which people take Enbrel and have Deafness neurosensory. It is created by eHealthMe based on reports of 633,316 people who have side effects when taking Enbrel from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
633,316 people reported to have side effects when taking Enbrel.
Among them, 344 people (0.05%) have Deafness neurosensory.
What is Enbrel?
Enbrel has active ingredients of etanercept. It is often used in rheumatoid arthritis. eHealthMe is studying from 635,044 Enbrel users for its effectiveness, alternative drugs and more.
What is Deafness neurosensory?
Deafness neurosensory is found to be associated with 1,417 drugs and 865 conditions by eHealthMe.
Number of Enbrel and Deafness neurosensory reports submitted per year:
Time on Enbrel when people have Deafness neurosensory *:
Gender of people who have Deafness neurosensory when taking Enbrel*:
Age of people who have Deafness neurosensory when taking Enbrel *:
Common drugs people take besides Enbrel *:
Common side effects people have besides Deafness neurosensory *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Enbrel and have Deafness neurosensory?Check whether Deafness neurosensory is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Deafness neurosensory and when was it recovered:
Expand to all the drugs that have ingredients of etanercept:
Alternative drugs to, pros and cons of Enbrel:
- Enbrel (635,044 reports)
Common Enbrel side effects:
- Drug ineffective: 90,931 reports
- Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints): 56,708 reports
- Joint pain: 49,585 reports
- Pain: 47,830 reports
- Fatigue (feeling of tiredness): 32,388 reports
- Rashes (redness): 29,268 reports
Browse all side effects of Enbrel:a b c d e f g h i j k l m n o p q r s t u v w x y z
Deafness neurosensory treatments and more:
- Deafness neurosensory (4,111 reports)
COVID vaccines that are related to Deafness neurosensory:
- Deafness neurosensory in Moderna COVID Vaccine
- Deafness neurosensory in Pfizer BioNTech Covid Vaccine
- Deafness neurosensory in Johnson and Johnson Covid Vaccine
Common drugs associated with Deafness neurosensory:
- Prednisone: 436 reports
- Methotrexate: 435 reports
- Tylenol: 379 reports
- Gabapentin: 344 reports
- Enbrel: 344 reports
- Celebrex: 341 reports
- Oxycontin: 318 reports
- Fosamax: 312 reports
- Nasonex: 307 reports
- Sulfasalazine: 301 reports
All the drugs that are associated with Deafness neurosensory:
- Deafness neurosensory (1,417 drugs)
Common conditions associated with Deafness neurosensory:
- Rheumatoid arthritis: 432 reports
- Osteoporosis: 284 reports
- Pain: 261 reports
- Arthritis: 248 reports
- High blood pressure: 161 reports
- Sleep disorder: 148 reports
All the conditions that are associated with Deafness neurosensory:
- Deafness neurosensory (865 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on etanercept (the active ingredients of Enbrel) and Enbrel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Keftab and Celebrex drug interaction - a second ago
- Gravol and Respiratory Tract Infection - 2 seconds ago
- Nitro-Dur and Tradjenta drug interaction - 14 seconds ago
- Pyridostigmine Bromide and Nifedipine drug interaction - 19 seconds ago
- Allegra and Electrolyte Depletion - 20 seconds ago
- Avelox and Daliresp drug interaction - 23 seconds ago
- Calcium and Restrictive Pulmonary Disease - 25 seconds ago
- Depakote and Drug Specific Antibody Present - 33 seconds ago
- Paxil and Verbal Abuse - 42 seconds ago
- Adempas and Injection Site Discoloration - 44 seconds ago